NIBAN3

Across TCGA pan-cancer cohorts, NIBAN3 RNA differs between tumor and matched normal tissue in 8 of 18 cancer types tested, making tumor–normal expression one of NIBAN3’s most consistent transcriptional readouts.

The strongest signal is observed in bladder urothelial carcinoma (BLCA), where NIBAN3 RNA is repressed in tumor relative to normal tissue. In most cancer types NIBAN3 is over-expressed in tumor, although a few such as BLCA and COAD show the opposite, repressed pattern.

BLCA, COAD, and BRCA are the cancer types where NIBAN3 tumor–normal differential expression is most reproducible.

RNA tumor vs normal associations by lineage

Ranked by sampling consensus. Fold-change is the tumor-versus-normal difference in NIBAN3 RNA (log₂); positive values indicate higher expression in tumor. p-values are from the differential-expression test.

Lineage	Gender	Stage	Fold-change	p	Sampling consensus
BLCA	All	III,IV	−0.742	.007	6	view →
COAD	Female	II,III,IV	−0.464	.001	6	view →
BRCA	Female	All	+0.176	.010	4	view →
LUSC	All	All	−0.370	.004	3	view →
PAAD	Male	All	−0.725	.031	2	view →
THCA	All	All	−0.469	.017	2	view →
KICH	All	All	−0.279	.018	2	view →
KIRC	All	All	+0.081	.038	1	view →

Pink = over-expressed in tumor, green = repressed in tumor. Showing the 8 strongest of 8 lineages.

NIBAN3–BLCA

Open the BLCA breakdown →